News

WuXi News

Filter By

2015/11/06

WuXi PharmaTech Congratulates Novira Therapeutics

SHANGHAI, November 6, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, congratulates our partner and WuXi Venture Fund portfolio company Novira Therapeutics for its agreement to be acquired by Johnson and Johnson.

Read more

2015/11/03

WuXi PharmaTech Announces Third-Quarter 2015 Results

WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: WX) announces the following financial information for the third quarter ended September 30, 2015.

Read more

2015/10/30

Gilead Sciences and WuXi PharmaTech Announce Collaboration for a Dedicated Analytical and Stability Testing Facility

SHANGHAI, Oct. 30, 2015 /PRNewswire/ -- Gilead Sciences, Inc., and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), today announced that they have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.

Read more

2015/10/23

WuXi PharmaTech Launches Medical Device Testing Services in China

SHANGHAI, October 23, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its Laboratory Testing Division (LTD) has launched preclinical medical device testing services in China. These services are being offered for Chinese and international clients for their product registration with the China Food and Drug Administration (CFDA) and for Chinese clients for product registration in global markets.

Read more

2015/10/19

Dr. Peter Schultz, CEO of The Scripps Research Institute, Visits WuXi AppTec Headquarters in Shanghai

SHANGHAI, October 19, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, announced today that Dr. Peter Schultz visited WuXi AppTec's Shanghai headquarters on October 17 and gave an inspiring public lecture. Dr. Schultz is the CEO of The Scripps Research Institute and the founder and Director of the California Institute for Biomedical Research. He is also a member of the National Academy of Sciences in the United States and of its Institute of Medicine.

Read more